论文部分内容阅读
目的:中医药联合表皮生长因子酪氨酸激酶受体抑制剂(EGFR-TKIs)治疗ⅢA-Ⅳ期非小细胞肺癌的有效性和安全性。方法:计算机检索Pub Med、Medline、EMbase、Cochrane Library中国生物医学文献数据库、中国知网、万方数据资源、维普数据资源等数据库,纳入中医药联合EGFR-TKIs单药治疗ⅢA-Ⅳ期非小细胞肺癌的随机对照试验。由两名评价者独立评价并交叉核对纳入研究质量,对纳入的同质研究采用Rev Man 5.2统计软件进行Meta分析。结果:共纳入15项研究,合计977例患者。Meta分析结果显示,与EGFR-TKIs单药相比,中医药联合EGFR-TKIs能改善疾病的控制率(RR=1.26,P<0.01,95%CI[1.15,1.39])、生活质量(RR=1.35,P<0.01,95%CI[1.21,1.52]),并减轻EGFR-TKIs单药治疗中皮疹、腹泻、恶心呕吐的不良反应。结论:中医药联合EGFRTKIs治疗ⅢA-Ⅳ期非小细胞肺癌比EGFR-TKIs单药有效。由于纳入研究较少,质量不高,该结论尚待更大规模的多中心的随机对照研究进一步验证。
Objective: To investigate the efficacy and safety of traditional Chinese medicine combined with epidermal growth factor tyrosine kinase receptor inhibitor (EGFR-TKIs) in the treatment of stage ⅢA-Ⅳ non-small cell lung cancer. Methods: The databases of PubMed, Medline, EMbase, Cochrane Library, China Biomedical Literature Database, China National Knowledge Infrastructure, Wanfang Data Resource and VIP Data Resource were searched by computer. A randomized controlled trial of cell lung cancer. Two reviewers independently assessed and cross-checked the quality of the included studies, and Meta-analysis was performed using the Rev Man 5.2 statistical software for the included homogeneous studies. Results: A total of 15 studies were included, totaling 977 patients. Meta-analysis showed that Chinese medicine combined with EGFR-TKIs improved disease control rate (RR = 1.26, P <0.01,95% CI [1.15,1.39]), quality of life (RR = 1.35, P <0.01, 95% CI [1.21, 1.52]), and alleviated the adverse reaction of rash, diarrhea and nausea and vomiting during the EGFR-TKIs monotherapy. Conclusion: The combination of TCM and EGFRTKIs in the treatment of stage ⅢA-Ⅳ non-small cell lung cancer is more effective than EGFR-TKIs alone. Due to the small number of studies included and poor quality, this conclusion is yet to be validated by a larger, multicenter randomized controlled trial.